Jazz Pharmaceuticals (JAZZ) Amortizatization of Intangibles (2016 - 2025)
Jazz Pharmaceuticals has reported Amortizatization of Intangibles over the past 16 years, most recently at $169.7 million for Q4 2025.
- Quarterly Amortizatization of Intangibles rose 6.82% to $169.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $654.7 million through Dec 2025, up 4.36% year-over-year, with the annual reading at $654.7 million for FY2025, 4.36% up from the prior year.
- Amortizatization of Intangibles was $169.7 million for Q4 2025 at Jazz Pharmaceuticals, up from $168.4 million in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $172.1 million in Q1 2022 and troughed at $68.2 million in Q1 2021.
- The 5-year median for Amortizatization of Intangibles is $155.1 million (2023), against an average of $150.8 million.
- Biggest five-year swings in Amortizatization of Intangibles: soared 152.37% in 2022 and later dropped 12.96% in 2023.
- Tracing JAZZ's Amortizatization of Intangibles over 5 years: stood at $157.3 million in 2021, then dropped by 12.66% to $137.4 million in 2022, then rose by 10.31% to $151.6 million in 2023, then grew by 4.85% to $158.9 million in 2024, then increased by 6.82% to $169.7 million in 2025.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods came in at $169.7 million, $168.4 million, and $162.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.